Here is the design of a clinical trial:

Official Title: Reduced Anticoagulation Targets in ECLS (RATE)

Included conditions:
- Heart Failure
- Respiratory Failure
- Extracorporeal Membrane Oxygenation
- Bleeding
- Thrombosis

Study Armgroups:
- {'label': 'Target of 2-2.5 times baseline aPTT (usual care, about 60-75)', 'type': 'ACTIVE_COMPARATOR', 'description': 'Administration of heparin during ECLS with an aPTT target of 2-2.5 times baseline.', 'interventionNames': ['Drug: Heparin']}
- {'label': 'Target of 1.5-2.0 times baseline aPTT (45-60 sec.)', 'type': 'ACTIVE_COMPARATOR', 'description': 'Administration of heparin during ECLS with an aPTT target of 1.5-2.0 times baseline.', 'interventionNames': ['Drug: Heparin']}
- {'label': 'LMWH guided by weight and renal function.', 'type': 'ACTIVE_COMPARATOR', 'description': 'Administration of LMWH guided by weight and renal function during ECLS.', 'interventionNames': ['Drug: LMWH']}

Interventions:
- {'type': 'DRUG', 'name': 'Heparin', 'description': 'Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.', 'armGroupLabels': ['Target of 1.5-2.0 times baseline aPTT (45-60 sec.)', 'Target of 2-2.5 times baseline aPTT (usual care, about 60-75)'], 'otherNames': ['Unfractionated heparin']}
- {'type': 'DRUG', 'name': 'LMWH', 'description': 'Administration of LMWH guided by weight and renal function during ECLS.', 'armGroupLabels': ['LMWH guided by weight and renal function.'], 'otherNames': ['Dalteparine', 'Enoxaparine', 'Nadroparine', 'Tinzaparine']}

Primary Outcomes:
- {'measure': 'Hemorrhagic complications', 'description': 'Severe hemorrhagic complications will be registered according to the Extracorporeal Life Support Organization (ELSO) definitions for major bleeding and is defined as clinically overt bleeding with a decrease in hemoglobin of at least 1,24 mmol/L (2 g/dl)/24 hours, or a transfusion requirement of ≥ 3 EH RBC over that same time period. Bleeding that is retroperitoneal, pulmonary or involves the central nervous system, or bleeding that requires surgical intervention is also considered major bleeding.', 'timeFrame': 'Through ECLS completion, an average of 14 days'}
- {'measure': 'Severe thromboembolic complications', 'description': 'Severe thromboembolic complication defined as ischemic stroke, limb ischemia, or acute pump failure', 'timeFrame': 'Through ECLS completion, an average of 14 days'}
- {'measure': 'Mortality', 'description': 'Mortality at 6 months', 'timeFrame': '6 months after ECLS'}

Please estimate the sample size based on the assumption: 
Non-inferiority with a significance level (alpha) of 5%, power of 80%, and a non-inferiority limit (delta) of 7.5%.
Sample size
        The RATE trial is powered for the primary composite endpoint: (1) severe hemorrhagic complications according to the ELSO definitions; (2) severe thromboembolic complication defined as ischemic stroke, limb ischemia, or acute pump failure; and (3) mortality at 6Â months. We estimate that cases reaching the composite endpoint decrease from 70% in the control arm to 60% in each intervention arm. This sample size calculation is made to show non-inferiority with a significance level (alpha) of 5%, power of 80%, and a non-inferiority limit (delta) of 7.5%. The corresponding sample size is 91 patients per arm. To compensate for a lower effect and potential drop-outs, 330 patients will be enrolled.